Degradable co-delivery nanoplatforms for inflammation-targeted therapy against atherosclerosis
Degradable co-delivery nanoplatforms for inflammation-targeted therapy against atherosclerosis
复制标题
用于抗动脉粥样硬化的炎症靶向治疗的可降解共递送纳米平台
DOI：
10.1016/j.apmt.2021.101214
复制
发表时间：
2021-10-21
影响因子：
8.3
通讯作者：
Li, Bo
中科院分区：
文献类型：
--
作者：
Wu, Zhaoyu;Xu, Zhijue;Li, Bo
Atherosclerosis is characterized by chronic inflammation of the arterial wall. Activated macrophages play a significant role in the inflammatory process of atherosclerosis by secreting inflammatory factors such as interleukin-1 (IL-1) and interleukin-6 (IL-6). Among all the several methods to treat atherosclerosis, anti-inflammatory therapy with copper ions and IL-1 receptor antagonist (IL-1Ra) are the most promising approaches, but they are limited by side effects on liver damage and the short in vivo half-life of IL-1Ra, respectively. Herein, we developed an inflammation-targeted nanoplatform, i.e. IL-1Ra-loaded copper doped mesoporous silica nanoparticles (IL-1Ra@Cu-MSNs), for co-delivery of IL-1Ra and copper ions. The nanoplatform showed outstanding drug-loading efficiency, sustained release property and biodegradability. Released copper ions specifically induced macrophage apoptosis by triggering ROS production. The loaded IL-1Ra conferred IL-1R-targeting and anti-inflammatory properties to the nanoplatform. In vivo study revealed that the IL-1Ra@Cu-MSNs significantly reduced arterial stenosis, plaque burden and macrophage infiltration due to the combined action of copper ions and IL-1Ra. Our work demonstrates that integration of targeted modulation of cellular function and inhibition of inflammation based on MSNs significantly alleviates arterial inflammation, which provides a novel strategy for the inflammation targeted therapy against atherosclerosis. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
